Media Relations

HOME>Company>Media Relations



Taejoon Pharmaceutical Co., Ltd. held an new CI proclamation ceremony

new CI.jpg

Taejoon Pharmaceutical Co., Ltd. ("Taejoon") held an annual kick-off meeting and new CI (Corporate Identity) proclamation ceremony at its headquarter in Hannam-dong, Seoul on January 2, 2017.

Taejoon Pharmaceutical's New Corporate Identity wordmark symbolizes, Taejoon's direction to go closer to customer with a image of reminiscent of smile. In this event, the introduction of new CI and the badge presentations to employees were done to emphasize unity of company.

Established in 1978, Taejoon is currently exporting the ophthalmic medicinal products manufactured at its EU-GMP approved facility which was the first EU-GMP approved manufacturing facility in Korea to many countries including the U.S., Europe and China.  It is also the world’s first contrast media specialized pharmaceutical company which has the technical skills in all three fields of vascular, MRI, and gastrointestinal contrast media. 

In 2012, Taejoon was selected as ‘Innovative Pharmaceutical Company’ and recertified in 2015 based on the capability in novel drug development activities and the overseas market expansion. 

prevTaejoon Pharmaceutical Co., Ltd. held an new CI proclamation ceremony
nextTaejoon Pharm. to Sponsor “Taejoon Ophthalmology Thesis Award” and “Taejoon Ophthalmology Service Award” in 2016